CLAIMS

1. A compound of Formula (I):



Formula (**I**)

or a pharmaceutically acceptable salt thereof.

2. A process for the preparation of a compound of formula (I), comprising the steps of reacting a compound of formula R1 with methyl 4-methoxybutyrate of formula R2 according to the following reaction scheme



Formula (**I**)

3. The process according to claim 2 wherein the reaction is carried out in presence of a catalyser based on NH4Cl.

4. The process according to claim 3 wherein NH4Cl is added in an amount

of 8 to 12% by weight with respect to the weight of reagent R_1.

5. The process according to anyone of claims 2 to 4 wherein the reagents R_1 and R_2 are equimolar.

6. The process according to anyone of claims 2 to 5 wherein the reaction is carried out at a temperature of 120 to 170°C.

7. The process according to anyone of claims 2 to 6 wherein the reagent methyl 4-methoxybutyrate R2 is prepared by reacting γ-butyrolactone R3 with methyl orthoformate R4 in an acidic environment, preferably using sulphuric acid and methanol as solvent according to the following reaction scheme:



R_3 R_4 P

8. A compound having the following formula or a pharmaceutically acceptable salt thereof



Formula (**I**)

for use as a medicament.

9. The compound of claim 1 or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of drug addiction.

10. A compound for use according to claim 9 in the prevention or treatment of a disorder selected from catalepsy, narcolepsy, insomnia, obstructive sleep apnea syndrome, depression, anxiety, insomnia associated with schizophrenia, excessive sedation, essential tremor, chronic fatigue syndrome, chronic insomnia or neuroprotection from detrimental substances.

11. A compound for use according to claim 9 in the prevention or treatment of alcohol misuse, alcoholism, alcohol use disorder.

12. A pharmaceutical composition comprising a compound of formula (I) according to claim 1, preferably in an amount of 50 to 500 mg, and a pharmaceutically acceptable carrier.

13. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention and/or treatment of drug addiction.

14. The use according to claim 13, wherein the medicament is for the prevention or treatment of a disorder selected from catalepsy, narcolepsy,

insomnia, obstructive sleep apnea syndrome, depression, anxiety, insomnia associated with schizophrenia, excessive sedation, essential tremor, chronic fatigue syndrome, chronic insomnia or neuroprotection from detrimental substances.

15. The use according to claim 13, wherein the medicament is for the prevention or treatment of alcohol misuse, alcoholism, alcohol use disorder.